Novel antibody helps patients with advanced gastric cancer live longer

Bookmark and Share
Published: 5 Jun 2016
Views: 1878
Rating:
Save
Prof Salah-Eddin Al-Batran - University Cancer Center, Frankfurt, Germany

Prof Al-Batran talks to ecancertv at ASCO 2016 about findings from a European phase II study which showed that the novel, first-in-class antibody IMAB362 can significantly extend median survival when added to standard chemotherapy (13.2 months vs. 8.4 months) for patients with advanced gastric cancer.

Watch the press conference and read the news story for more.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.